Greenwich Stock Financials

GLSI -  USA Stock  

USD 8.66  0.24  2.70%

Understanding current and past Greenwich Lifesciences Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Greenwich Lifesciences' financial statements are interrelated, with each one affecting the others. For example, an increase in Greenwich Lifesciences' assets may result in an increase in income on the income statement. Because of this, it is necessary to analyze all of Greenwich Lifesciences' financials over time to get the whole picture.
The current Earnings Before Interest Taxes and Depreciation Amortization EBITDA is estimated to decrease to about (4.9 M). The current Earnings before Tax is estimated to decrease to about (4.9 M).
Please harness Greenwich Lifesciences fundamental data analysis to find out if markets are presently mispricing the company. We are able to interpolate and collect twenty-one available reported financial drivers for Greenwich Lifesciences, which can be compared to its competitors. To make sure the equity is not overpriced, please check out all Greenwich Lifesciences financials, including its price to book, as well as the relationship between the total debt and earnings per share . Given that Greenwich Lifesciences has a cash and equivalents of 27.2 M, we strongly advise you to confirm Greenwich Lifesciences regular market performance to make sure the company can sustain itself down the road. Use Greenwich Lifesciences to protect your portfolios against small market fluctuations. The stock experiences an unexpected downward movement. The market is reacting to new fundamentals. Check odds of Greenwich Lifesciences to be traded at $8.31 in 90 days.
  
Refresh
With this module, you can analyze Greenwich financials for your investing period. You should be able to track the changes in Greenwich Lifesciences individual financial statements over time to develop the understanding of its risk, liquidity, profitability, or other critical and vital indicators.
The fundamental analysis of Greenwich Lifesciences is a critical element in measuring its lifeblood. The essential information of the day-to-day investment outlook for Greenwich Lifesciences includes many different criteria found on its balance sheet. For example, investors should never minimize Greenwich Lifesciences' ability to pay suppliers or employees on time, making sure interest payments are not accumulating or correctly timing where and how to re-invest extra cash. Any individual investor needs to monitor Greenwich Lifesciences' cash flow, debt, and profitability to effectively and accurately make more informed decisions on whether to invest in Greenwich Lifesciences.

Greenwich Lifesciences Cash

Chance Of Financial Distress
Over 62
Greenwich Lifesciences has more than 62 (%) percent chance of experiencing financial distress in the next two years of operations. The calculation of odds of distress for Greenwich Lifesciences stock is tightly coupled with the Probability of Bankruptcy. It complements the equity performance score by supplying investors with insight into company financials without requiring them to know too much about all of the complex accounting and financial indicators surrounding the entity. More Info
The data published in Greenwich Lifesciences' official financial statements usually reflect Greenwich Lifesciences' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Greenwich Lifesciences. For example, before you start analyzing numbers published by Greenwich accountants, it's critical to develop an understanding of what Greenwich Lifesciences' liquidity, profitability, and earnings quality are in the context of the Healthcare space in which it operates.
Please note, the presentation of Greenwich Lifesciences' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Greenwich Lifesciences' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Greenwich Lifesciences' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Greenwich Lifesciences. Please utilize our Beneish M Score to check the likelihood of Greenwich Lifesciences' management to manipulate its earnings.

Greenwich Lifesciences Company Summary

Greenwich Lifesciences competes with Berkeley Lights, and Brickell Biotech. Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2neu-expressing cancers. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas. Greenwich Lifesciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 3 people.
Specialization
Healthcare, Biotechnology
InstrumentUSA Stock View All
ExchangeNASDAQ Exchange
CUSIP396879108
LocationTexas; U.S.A
Business AddressBuilding 14
SectorHealthcare
IndustryBiotechnology
BenchmarkDOW
Websitegreenwichlifesciences.com
Phone832 819 3232
CurrencyUSD - US Dollar
You should never invest in Greenwich Lifesciences without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Greenwich Stock, because this is throwing your money away. Analyzing the key information contained in Greenwich Lifesciences' financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.

Greenwich Lifesciences Key Financial Ratios

Generally speaking, Greenwich Lifesciences' financial ratios allow both analysts and investors to convert raw data from Greenwich Lifesciences' financial statements into concise, actionable information that can be used to evaluate the performance of Greenwich Lifesciences over time and compare it to other companies across industries. There are many critical financial ratios that investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Greenwich Lifesciences reports annually and quarterly.

Greenwich Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Greenwich Lifesciences's current stock value. Our valuation model uses many indicators to compare Greenwich Lifesciences value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Greenwich Lifesciences competition to find correlations between indicators driving Greenwich Lifesciences's intrinsic value. More Info.
Greenwich Lifesciences is one of the top stocks in earnings per share category among related companies. It is one of the top stocks in cash flow from operations category among related companies . The current Net Cash Flow from Operations is estimated to decrease to about (4.4 M). The current Free Cash Flow is estimated to decrease to about (4.4 M). Comparative valuation analysis is a catch-all model that can be used if you cannot value Greenwich Lifesciences by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Greenwich Lifesciences' Stock . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Greenwich Lifesciences' earnings, one of the primary drivers of an investment's value.

Greenwich Lifesciences Systematic Risk

Greenwich Lifesciences' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Greenwich Lifesciences volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty with a total number of output elements of fourty-one. The Beta measures systematic risk based on how returns on Greenwich Lifesciences correlated with the market. If Beta is less than 0 Greenwich Lifesciences generally moves in the opposite direction as compared to the market. If Greenwich Lifesciences Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Greenwich Lifesciences is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Greenwich Lifesciences is generally in the same direction as the market. If Beta > 1 Greenwich Lifesciences moves generally in the same direction as, but more than the movement of the benchmark.
.

About Greenwich Lifesciences Financials

What exactly are Greenwich Lifesciences Financials? Typically, a company's financial statements are the reports that show the financial position of the company. Three primary documents fall into the category of financial statements. These documents include Greenwich Lifesciences' income statement, its balance sheet, and the statement of cash flows. Potential Greenwich Lifesciences investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Greenwich Lifesciences investors may use each financial statement separately, they are all related. The changes in Greenwich Lifesciences's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Greenwich Lifesciences's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.
There are several different ways that investors can use financial statements to try and predict whether a stock price will go up or down. Unfortunately, there is no surefire formula, but there are some general guidelines that you should keep in mind when looking at the numbers. First, realize what kind of company it is so you know if its revenues are more likely to grow or shrink over time. For example, a software company's revenue is expected to increase year after year due to new products and services that its customers will want to buy. At the same time, a car manufacturer might not be able to sell as many cars when the economy slows down, so it would have less net income during those times. Second, pay attention to its debt to equity ratio because this number will tell you how much risk it has. If a company such as Greenwich Lifesciences is not taking on any additional risks, its debt-to-equity should be less than one. As a general rule of thumb, if the market value or book value (which can be found in the footnotes) of assets exceeds the company's liabilities, then it is probably in good shape. Finally, use other financial statements to try and figure out if a stock price will go up or down because investors are always looking for growth opportunities when they buy new stocks. For example, if you see that net revenue of Greenwich grown by more than 25% over the last five years, then there is a good chance that it will continue growing at least by 20% or more each year. On the other hand, if you see that net revenue has only grown by about 15%, which is barely above inflation levels, then chances are it will not grow much faster than this over time, and investors may shy away from buying it.

Greenwich Lifesciences May 22, 2022 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of Greenwich Lifesciences help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Greenwich Lifesciences. We use our internally-developed statistical techniques to arrive at the intrinsic value of Greenwich Lifesciences based on widely used predictive technical indicators. In general, we focus on analyzing Greenwich Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Greenwich Lifesciences's daily price indicators and compare them against related drivers.
Information Ratio(0.22)
Maximum Drawdown21.91
Value At Risk(8.38)
Potential Upside5.66
Please check Risk vs Return Analysis. Note that the Greenwich Lifesciences information on this page should be used as a complementary analysis to other Greenwich Lifesciences' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.

Complementary Tools for Greenwich Stock analysis

When running Greenwich Lifesciences price analysis, check to measure Greenwich Lifesciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Greenwich Lifesciences is operating at the current time. Most of Greenwich Lifesciences' value examination focuses on studying past and present price action to predict the probability of Greenwich Lifesciences' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Greenwich Lifesciences' price. Additionally, you may evaluate how the addition of Greenwich Lifesciences to your portfolios can decrease your overall portfolio volatility.
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Go
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Go
Shere Portfolio
Track or share privately all of your investments from the convenience of any device
Go
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Go
Equity Valuation
Check real value of public entities based on technical and fundamental data
Go
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Go
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Go
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Go
Is Greenwich Lifesciences' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Greenwich Lifesciences. If investors know Greenwich will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Greenwich Lifesciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Greenwich Lifesciences is measured differently than its book value, which is the value of Greenwich that is recorded on the company's balance sheet. Investors also form their own opinion of Greenwich Lifesciences' value that differs from its market value or its book value, called intrinsic value, which is Greenwich Lifesciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Greenwich Lifesciences' market value can be influenced by many factors that don't directly affect Greenwich Lifesciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Greenwich Lifesciences' value and its price as these two are different measures arrived at by different means. Investors typically determine Greenwich Lifesciences value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Greenwich Lifesciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.